title: Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer.
authors: A
authors: A
authors: Muñoz
authors: S
authors: S
authors: Carrera
authors: J
authors: J
authors: Ferreiro
authors: A Ruiz
authors: AR
authors: de Lobera
authors: J M
authors: JM
authors: Mañé
authors: G
authors: G
authors: López-Vivanco
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D008099:Liver / Q000187:drug effects*; D008565:Membrane Proteins / Q000235:genetics; D017354:Point Mutation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C103673:HFE protein, human